HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma

Journal of Medical and Dental Sciences

Volumn 57, Issue 2, 2010, Pages 155-163

  Horiguchi, Shin Ichiro ^a,b   Hishima, Tsunekazu ^b   Hayashi, Yukiko ^b   Shiozawa, Yumiko ^b   Horiguchi, Kazumi ^b   Kuroi, Katsumasa ^b   Toi, Masakazu ^c   Funata, Nobuaki ^b   Eishi, Yoshinobu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Cytoplasmicstaining; HER2 neu; Immunohistochemistry; Neuroendocrine differentiation

Indexed keywords

CD56 ANTIGEN; CHROMOGRANIN A; COLORING AGENT; DIAGNOSTIC AGENT; ENOLASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; BREAST TUMOR; CELL DIFFERENTIATION; CHEMISTRY; COLLOID CARCINOMA; CYTOPLASM; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; NEUROSECRETORY CELL; PAGET NIPPLE DISEASE; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIFFERENTIATION; CHROMOGRANIN A; COLORING AGENTS; CYTOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEUROENDOCRINE CELLS; PHOSPHOPYRUVATE HYDRATASE; RECEPTOR, ERBB-2; SYNAPTOPHYSIN; YOUNG ADULT;

EID: 77956161530     PISSN: 13428810     EISSN: 13428810     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004; 319: 1-11.
2. Kay EW, Walsh CJ, Cassidy M, et al. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994; 47: 816-22.
3. Keshgegian AA. ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically and immunohistochemically determined hormone receptors. Breast Cancer Res Treat 1995; 35: 201-10.
4. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195: 422-8.
5. Hanna W. Testing for HER2 status. Oncology 2001; 61 Suppl 2: 22-30.
6. Keshgegian AA, Cnaan A. erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol 1997; 108: 456-63.
7. Hanna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Mod Pathol 1990; 3: 455-61.
8. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-62.
9. Scott GK, Robles R, Park JW, et al. A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol. 1993 Apr;13(4):2247-57.
10. Egeblad M, Mortensen OH, Jäättelä M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer 2001 Oct 15;94(2):185-91.
11. Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004 Jan 22;23(3):646-53.
12. Sáez R, Molina MA, Ramsey EE, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res. 2006 Jan 15;12(2):424-31.
13. Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology 2002; 40: 215-22.
14. Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: a review. Virchows Arch 1994; 425: 449-57.
15. Sapino A, Righi L, Cassoni P, et al. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol 2001; 14: 768-76.
16. Tse GM, Ma TK, Chu WC, et al. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. Mod Pathol 2004; 17: 568-72.
17. Sugg SL, Ezzat S, Zheng L, et al. Cytoplasmic staining of erbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clin Endocrinol (Oxf) 1998; 49: 629-37.
18. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004; 29: e1-8.
19. Saeger W, Fassnacht M, Reincke M, et al. Expression of HER-2/neu receptor protein in adrenal tumors. Pathol Res Pract 2002; 198: 445-8.
20. Myers RB, Srivastava S, Oelschlager DK, et al. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994; 86: 1140-5.
21. Taylor SL, Platt-Higgins A, Rudland PS, et al. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer 1998; 76: 459-63.
22. Taylor SL, Rudland PS, Barraclough R. C-erbB-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2. Oncol Res 1999; 11: 311-7.
23. Lilleng R, Hagmar BM, Nesland JM. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast. Mod Pathol 1992; 5: 41-7.
24. Nesland JM, Ottestad L, Heikilla R, et al. C-erbB-2 protein and neuroendocrine expression in breast carcinomas. Anticancer Res 1991; 11: 161-7.
25. Tavassoli FA, Devillee P, editors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARCPress: Lyon; 2002.432 pp
26. Hayashi Y, Fukayama M, Shiozawa Y, et al. Incorporation of human chorionic gonadotropin alpha-subunit into different types of granule in stomach endocrine cells. An immunoelectron microscopic study. Acta Pathol Jpn 1989; 39: 737-42.
27. Singleton TP, Niehans GA, Gu F, et al. Detection of cerbB-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 1992; 23: 1141-50.
28. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-65.
29. Corbett IP, Henry JA, Angus B, et al. NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol 1990; 161: 15-25
30. De Potter CR, Quatacker J, Maertens G, et al. The subcellular localization of the neu protein in human normal and neoplastic cells. Int J Cancer 1989; 44: 969-74.
31. Coombs LM, Pigott DA, Sweeney E, et al. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer 1991; 63: 601-8.
32. Makretsov N, Gilks CB, Coldman AJ, et al. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003; Oct;34(10):1001-8.
33. Sapino A, Papotti M, Righi L, et al. Clinical significance of neuroendocrine carcinoma of the breast. Ann Oncol 2001; 12 Suppl 2: S115-7.
34. Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology 2002; 40: 211-4.